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Abstract
The role of negatively charged amino acids in the F-loop of the β4 subunit in channel activation and desensitization was studied using the patch-
clamp technique. The selected amino acids were changed to their neutral analogs via point mutations.Whole-cell currents were recorded in COS cells
transiently transfected with the α3β4 nicotinic acetylcholine receptor. The application of acetylcholine (ACh), nicotine (Nic), cytisine (Cyt),
carbamylcholine (CCh) and epibatidine (Epi) to cells clamped at −40 mV produced inward currents which displayed biphasic desensitization. The
EC50 of Epi and Nic were increased by a factor of 3–6 due to mutations D191N or D192N. Only Epi remained an agonist in the double-mutated
receptors with EC50 increased 17-fold. The interaction of the receptors with the competitive antagonist (+)tubocurarine (TC) was weakened almost 3-
fold in the double-mutated receptors. The mutations increased the proportion of the slower desensitization component and increased the response
plateau, resulting in decreased receptor desensitization. The double mutation substantially accelerated the return from long-term desensitization
induced by Epi.
© 2008 Elsevier B.V. All rights reserved.Keywords: Nicotinic acetylcholine receptor; α3β4; Epibatidine; F-loop1. Introduction
Nicotinic types of acetylcholine receptors (nAChR) are ligand-
gated ion channels comprised of five subunits forming the
central pore. nAChRs are activated from agonist binding sites
localized to the boundary between the α and neighbouring
subunits (for a review, see [1]). The binding of two agonist
molecules to the receptor is necessary to induce or stabilize
conformational changes of the channel complex which lead to
the opening of the cation-selective channel [2,3]. In the prolon-
ged presence of the agonist, the receptor enters an inactive
desensitized state [4,5]. Significant structural parts of the neu-
ronal receptor controlling fast and slow desensitization were
summarized by Giniatullin et al. [6].⁎ Corresponding author. Tel.: +420 29644 2551; fax: +420 29644 2488.
E-mail address: krusek@biomed.cas.cz (J. Krůšek).
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doi:10.1016/j.bbamem.2008.01.010Binding sites are composed of two parts, principal and
complementary, the first of which is always formed by an α
subunit. The complementary part is formed by a β subunit in
heteromeric neuronal nAChRs, whereas this role is played by a
δ, γ or ɛ subunit in muscle types. Thus, from the point of view
of function and position in the receptor, neuronal β4 subunits
are more related to muscle δ, γ and ɛ subunits than to the muscle
β1 subunit. In contrast to muscle nAChRs with two different
binding sites, it is reasonable to suppose that both binding sites
in α3β4 receptors are identical or almost identical, since not
only their principal but also their complementary parts are
formed by identical subunits. Several conserved negatively
charged amino acids in the F-loop of the δ, γ and ɛ subunits are
functionally important and hypothetically could interact with
the positively charged moiety of cholinergic agonists. Never-
theless, it was concluded that at least in the case of the ɛ and δ
subunits, their influence on channel gating or allostery is more
important than their disputable participation in agonist binding
[7–10]. Fig. 1 shows an amino-acid sequence comparison of the
Fig. 1. Section of amino-acid sequence alignment of rat (Rattus sp.) nicotinic receptor subunits and Lymnaea stagnalis acetylcholine-binding protein (AChBP).
Horizontal lines separate four functionally distinct groups of subunits. From top to bottom: subunits participating in the formation of both the principal and
complementary face of the agonist binding site (AChBP, α7), subunits forming exclusively the principal face (α1, α3, α4), subunits forming exclusively the
complementary face (β2, β4, γ, δ, ε), and β1, which is thought to not contribute to binding site formation. An abundance of negative-charged residues (highlighted
with black background) can be seen in the F-loop region in all cases, yet no overall pattern of their distribution can be deduced. Sporadic positively charged residues are
highlighted with grey background. Sequence numbering corresponds to the β4 subunit.
865J. Lindovský et al. / Biochimica et Biophysica Acta 1778 (2008) 864–871F-loop and its vicinity in β4 with several related subunits and
acetylcholine-binding protein (AChBP). Note that AChBP, which
is used for constructing models of nicotinic receptors [11,12]
shows only a low homology to the receptor subunits in the region
of loop F [13]. In general, F-loops are rich in negatively charged
amino acids, though their exact position within the loop differs.
Of the most preserved, the glycine-glutamate-tryptophan motif
(GEW) at positions 197–199 is present in all subunits except for
muscleβ1 and AChBP. Two, three or four consecutive negatively
charged residues (starting after position 185 in Fig. 1) can be
found in muscle γ, ɛ and δ subunits, respectively. Another motif
of two consecutive aspartates at positions 191–192 is unique to
the closely related β4 and β2 subunits (Ligand-gated ion channel
database: http://www.ebi.ac.uk/compneur-srv/LGICdb/HTML/
catphylogen.php). The E198, D200 pair is also present in
human, chick and bovine α7 subunits and in δ mouse, the
aspartate is replaced by a glutamate. In chick α7, the receptor
amino acids 161–172 (belonging to loop V, partially homologous
to loop F) are thought to participate in Ca2+ and agonist binding.
Mutation of the negative glutamate 172 strongly influences the
Hill coefficient and EC50 in a calcium-dependent manner [14].
Our goal was to identify those negatively charged amino
acids in the loop F of the β4 subunit which could be important
both for interaction with a positively charged moiety of agonists
and competitive antagonists and for receptor activation and
desensitization.
2. Materials and methods
Experiments were performed on COS cells, transiently transfected using a
Lipofectamine 2000 procedure (Gibco BRL) with plasmids coding the appropriate
subunit combination. Cells were cultivated in a minimal essential medium which
was supplemented with 10% fetal calf serum (both from Sigma Chemical, St.
Louis, MO). The cDNA coding the α3 and β4 subunits of rat neuronal nAChR
were obtained from Dr. S. Heinemann. The cDNAs were subcloned into the
pcDNA3.1 expression vector (Invitrogen) at the multiple cloning site. Point mu-
tations were introduced using Pfu Turbo DNA polymerase (Stratagene) and
primers coding mutated nucleotides (VBC Biotech, Austria). Successfully trans-
fected cells were detected by cotransfection with the CD4 coding plasmid (kindly
provided by Dr. G. Westbrook) and Dynabeads M-450 CD4 (Dynal Biotech,
Norway) aggregation control. More than 48 h after the transfection, whole-cell
patch-clamp measurements were performed using an Axopatch 200A amplifier
(Axon Instruments, Foster City, CA). Fire-polished glass micropipettes with an
outer diameter of about 3 μm were filled with a solution of the followingcomposition (in mM): CsF 110, CsCl 30, MgCl2 7, EGTA 2, HEPES–CsOH 10,
and Na2ATP 5; pH was 7.4. The resulting resistances of the microelectrodes were
from 2.5–6 MΩ. The cell bath solution contained (in mM): NaCl 160, KCl 2.5,
CaCl2 1,MgCl2 2,HEPES–NaOH10, and glucose 10; pHwas 7.3. Cells were kept
at a holding potential of −40 mV. Solutions of drugs (all from Sigma Chemical, St.
Louis, MO) were applied using a rapid perfusion system consisting of an array of
ten parallel quartz–glass tubes, each 400 μm in diameter. Both the positioning of
the tubes and switching on and off of the flow of different solutions were
synchronized under microcomputer control [15,16]. A complete change of the
solution around the cell could be carried out in 30–60ms. For signal recording and
evaluation of the data, an Axon Instruments Digidata 1320A digitizer and pClamp
9 software package (Axon Instruments, Foster City, CA)were used.Datawere low-
pass filtered at 1 kHz and digitized at 2 kHz. Concentration–response curves were
fitted to the Hill equation:
I Cað Þ ¼ C
nH
a
CnHa þ ECnH50
ð1Þ
where Ca is the agonist concentration, I(Ca) is the relative value of membrane
current, EC50 is the agonist concentration inducing 50% of the maximal response,
and nH is the Hill coefficient.
The decay phases of the current responses were fitted to two exponentials
with an added constant plateau component using the program Clampfit 9 (Axon
Instruments, Foster City, CA) and the relationship:
A tð Þ ¼ A1de
t
s1 þ A2de
t
s2 þ C ð2Þ
where A1, τ1 and A2, τ2 are the amplitudes and time constants of the two
components of desensitization, respectively. C is the amplitude of the non-
desensitizing component of the response, the final plateau. For further analy-
sis, the amplitudes were normalized to the peak value for each response:
a1=100%·(A1/Amax); a2=100%·A2/Amax; c=100%·C/Amax.
Inhibition curves were fitted to the simple inhibition curve:
I Cið Þ ¼ 1 CiCi þ IC50 ð3Þ
where Ci is the antagonist concentration, I(Ci) is the relative value of the
membrane current and IC50 is the antagonist concentration that inhibits 50%
of the response. IC50 was used to calculate the inhibition constant Ki, which
is independent of the EC50 and concentration of the agonist, according to
the Cheng–Prusoff formula modified for a receptor with cooperative agonist
binding [17–19]
Ki ¼ IC50
2þ CaEC50
 nH  1nH
1
ð4Þ
Statistical analysis was performed after transforming the concentration data
to −log values indicated as pEC50, pIC50 and pKi as the distribution of errors
Table 1
Activation of wild-type α3β4 receptor
Agonist pEC50 EC50 (μM) nH Imax/ImaxEpi (%) n
Epi 6.2±0.1 0.6 1.7±0.25 100 4
Nic 4.13±0.07 75 1.8±0.1 65±4 6
ACh 3.70±0.03 198 2±0.1 61±5 7
Cyt 3.92±0.01 120 1.9±0.1 61±9 7
CCh 2.76±0.07 1700 1.9±0.04 73±19 3
pEC50=−log(EC50), nH is the Hill coefficient, Imax/ImaxEpi is the maximal
response relative to Epi and n is the number of cells.
Fig. 3. Effect of mutations within the F-loop on concentration–response curve for
Epi and Nic. The relative amplitudes of the responses of wild-type and mutated
receptors are normalized to the corresponding maximal response to Epi (set to
100%). Information comparing themaximal response amplitudes between different
types of receptors (efficacy of channel opening) is not available. Experimental data
points were fitted to theHill equation with the exception of the Nic responses of the
double-mutated receptor.
Fig. 2. Activation of wild-type α3β4 receptors by various agonists. A) Examples
of current responses induced by 7 s application of Epi (5 μM), Cyt (100 μM), Nic
(100 μM), ACh (300 μM) and CCh (1000 μM) in cell clamped at −40 mV. B)
Concentration–response curves for the peak currents induced by various agonists
of the α3β4 nicotinic receptor (Epi, Cyt, Nic, ACh, CCh). Experimental data
points were fitted to the Hill equation. Note that Epi acts with the highest potency
and efficacy. COS cells were clamped at −40 mV.
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values of EC50, IC50 and Ki are therefore given as means and their −log value
(indicated as pEC50, pIC50 and pKi)±S.E.M. in parenthesis. The statistical
significance of the differences between Ki values was determined by T-test
(SigmaPlot 6, SPSS Inc. Chicago, IL) performed on sets of pKi values with a
significance level of 0.05.
3. Results
3.1. Activation
The locations for point mutations in the glutamate and
aspartate in the F-loop of the β4 subunit were chosen to be
analogous to the negatively charged amino acids in the F-loops of
other subunits forming the complementary part of the agonist
binding sites. Cells with wild-type α3β4 receptors and receptors
with the β4 subunit mutated in the E198Q, D200N, D191N,
D192N, and D191N+D192N positions were stimulated by the
application of a solution containing the indicated concentration of
Epi, Nic, Cyt and ACh. Mutated receptors formed functional
chemically activated channels, but their sensitivity to particular
agonists was different. The responses of all constructs were
compared with those of wild-type receptors. Generally, the rapid
application of Epi to successfully transfected cells (10–90% from
total in the dish), evoked desensitizing inward ionic currents as
high as 5 nÅ in whole-cell patch-clamp mode at −40 mV. The
whole-cell responses of all variants ofα3β4 receptors are strongly
rectified (not shown) and no measurable responses could be
induced at positive membrane potentials [20,21].
3.1.1. Wild-type
Wild-type (WT) concentration–response curves were fitted
to the Hill Eq. (1) and a comparison of its sensitivity to variousagonists is given in Fig. 2 and Table 1. Epi is the agonist with
the lowest EC50. The EC50 values for Nic, ACh and Cyt were
similar, but the estimated EC50 value for CCh was one order of
magnitude higher. The maximal responses to Nic, ACh, Cyt and
CCh were smaller and only reached 60–70% of the maximal
responses to Epi.
3.1.2. Mutations
As the difference in the maximal current amplitude of the
responses to a specific agonist between wild-type and mutated
receptors could not be estimated directly, only the relative chan-
ges in amplitude between agonists were estimated. It was only
possible to construct reliable concentration–response curves for
all mutated receptors with Epi. Therefore, we compared the
saturating response to Epi in every receptor variant with the
maximal responses to the various agonists to estimate relative
efficacy changes. Mutations E198Q and D200N have virtually
no effect on receptor activation and EC50 values (not shown).
The change in functionality of D191N- and D192N-mutated
receptors was different for the various agonists. Only for two
agonists (Epi and Nic) could concentration–response curves be
constructed for single mutations (Fig. 3) and the results are
shown in Table 2. The EC50 for the Epi activation of D191N and
Table 2
Activation of mutated α3β4 receptors
Agonist – receptor pEC50 EC50 (μM) nH EC50mut/
EC50WT
n
Epi – D191N 5.44±0.07 3.65 1.52±0.04 6.1 6
Epi – D192N 5.75±0.18 1.76 1.4±0.2 2.9 4
Epi – D191N+
D192N
4.98±0.05 10.5 1.64±0.1 17.5 4
Nic – D191N 3.35±0.09 440 – 5.9 3
Nic – D192N 3.5±0.03 315 – 4.2 5
pEC50=−log(EC50), nH is the Hill coefficient, EC50mut/EC50WT is a relative
increase of EC50 and n is the number of cells.
Table 3
Parameters of wild-type receptors desensitization
Agonist τ1 (s) τ2 (ms) a1 (%) a2 (%) c (%)
ACh 1.1±0.1 190±20 64±2 28±3 6.3±0.5
Nic 1±0.03 200±20 56±3 40±3 4.4±0.6
Epi 1.6±0.3 200±20 11±1 82±3 2±0.5
τ1 and τ2 are time constants of desensitization, a1, a2 and c are the corresponding
relative amplitudes of the individual components and the plateau.
Fig. 4. Effects of selected mutations on desensitization kinetics of α3β4 receptor
responses. Epi was used as the agonist in all cases; its concentration was set near
the EC50 value of the individual receptor variants: 1 μM, 10 μM, 5 μM and
30 μM in the wild-type, D191N, D192N and D191N+D192N, respectively. A)
The time course of responses of wild-type and mutated α3β4 receptors. B) The
relative contribution of the slow (a1) and fast (a2) desensitization components
and the final plateau (c) component to the total peak current amplitude. C) The
slow (τ1) and fast (τ2) desensitization time constants. Note marked prolongation
of the slower component τ1 in all mutated receptors, substantial increase in the
plateau level in the double-mutated receptor and decreased contribution of the
faster component a2.
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double-mutated receptor D191N+D192N, Epi EC50 was 17.5
times as high as in the WT, which almost perfectly corresponds
to the additive action of the two individual mutations.
Nic remained an agonist with the D191N and D192N
mutations but its relative efficacy was decreased (14±9% and
17±5% of the Epi maximal response in D191N and D192N,
respectively) and the concentration–response curves could have
been deformed. With D191N+D192N, Nic was only able to
induce responses at a concentration of 3 mM. It was therefore
impossible to construct a concentration–response curve and no
EC50 value was estimated. The amplitude of this response
amounts to 9.9±0.7% of the maximal Epi response.
The activation ability of ACh and Cyt was inhibited by the
D191N and D192N mutations to such a degree that their
maximal responses only reached 10–20% of the Epi response
value at high agonist concentration (higher than 3 mM) and no
concentration–response curve could be constructed. CCh was
completely ineffective at activating these two mutated receptors
(not shown). ACh, Cyt and CCh were completely ineffective at
activating D191N+D192N receptors. To clarify to what extent
these ligands could bind to double-mutated receptors, they were
used as competitive antagonists to Epi as described in Section
3.3.
3.2. Desensitization
In control wild-type responses to 200 μM ACh, 75 μM Nic
and 1 μMEpi, the time course of current decay was fitted to two
exponential components plus a constant plateau. The time
constants τ1, τ2, as well as the normalized amplitudes a1, a2 of
two exponentials and the normalized plateau c varied between
cells and also between the responses in one cell. The time
constants of the wild-type responses to ACh, Nic and Epi were
similar but the relative proportions of the individual compo-
nents differed markedly between ACh and Nic on one side and
Epi on the other side (Table 3). In Epi responses, it was
predominantly the shorter component that formed the shape of
the responses and the constant plateau was hardly detectable. In
contrast, the longer time constant components made a major
contribution to the responses of ACh and Nic and the shorter
components were slightly smaller. Also, the constant plateau
was more expressed in ACh and Nic responses.
The desensitization parameters of different mutated receptors
were estimated using the same approach. However, in order toensure reliable and comparable responses, the Epi concentration
for each receptor variant had to be chosen close to its appro-
priate EC50 value. Therefore concentrations of 10 μM, 5 μM
and 30 μM were used for the D191N, D192N and D191N+
D192N mutations, respectively. The time constants and com-
ponent amplitudes as well as examples of individual responses
of wild-type and mutated receptors to Epi are summarized in
Fig. 4.
Both, the time course of decay and degree of desensi-
tization were profoundly altered, particularly in D191N and
the D191N+D192N double mutation. The amplitudes of pla-
teau c and of slower component a1 were increased and its time
constant τ1 was prolonged. The amplitude of faster component
a2 was decreased. The overall result of such changes was that
Fig. 5. Effect of selected mutations on Epi-induced long-term desensitization and
receptor recovery. Receptors were stimulated by 7 s application of Epi at 90 s
intervals. Epi was used at the concentration of its EC50 for individual receptor
variants. A) In the wild-type, repetitive application of Epi strongly diminished
responses after several successive applications. B) The double mutation D191N
+D192N hardly exhibited this progressive decrease of responses at all. C)
Summary of effect of repetitive stimulation on selected mutations. Mutations
D191N and D191N+D192N caused almost complete recovery from desensitiza-
tion during each 90 s gap.
Table 4
Inhibition of Epi responses by TC and partial agonists
Inhibitor – receptor pKi Ki (μM) n
TC – WT 5.2±0.2 6 12
TC – D191N 5.16±0.2 6.9 6
TC – D192N 5.24±0.1 5.8 4
TC – D191N+D192N 4.78±0.1 16.7 10
ACh – D191N+D192N 2.7±0.1 1864 5
Nic – D191N+D192N 3.57±0.1 271 6
CCh – D191N+D192N 2.35±0.2 4410 5
pKi=−log(Ki), and n is the number of cells.
Fig. 6. Inhibition of wild-type and mutated α3β4 receptors. Concentration–
inhibition curves of Epi responses blocked by antagonist TC in the wild-type
(Epi 0.6 μM) and by TC, Nic, ACh and CCh in D191N+D192N double-
mutated receptors (Epi 10 μM). Experimental data points were fitted to the Hill
equation (nH=1) with the exception of CCh points.
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than the Epi responses of the α3β4 WT, which desensitized
almost completely in a few seconds. The plateau was 2% in the
WT and 5% in the D191N and D192N single mutations,
whereas double-mutated receptor responses desensitized mark-
edly slowly and had their plateau at about 30% of the maxi-
mum. The application of higher concentrations of Epi to the
WT or D192N mutation led to long-term desensitization and
to a pronounced decrease in subsequent responses to any
cholinergic agonist. This long-term desensitization was
removed after at least 10 min of washing with control solution.
Such a slow recovery prevented any experimental mapping of
the time course of recovery from desensitization. Instead, the
decrease in the response peak value during repetitive 7-second
applications of Epi at 90 s intervals was measured (Fig. 5). In
the WT, after 3 successive applications the response dropped
to less than 20% of the control and decreased even more with
further applications. Such a progressive decrease reflects a very
slow time constant of recovery from the desensitized state,
which must be substantially longer than the 90 s gap between
the responses. The decrease in the peak values during repetitive
stimulation of the D192N (Fig. 5C), E198Q and D200N (not
shown) mutants was slower and less complete, however the
reproducibility of successive responses remained unsatisfac-
tory. In contrast to these receptors, D191N receptor responses
decreased only slightly during repetitive application of Epi
and it was only in D191N+D192N receptors that responses to
repetitive stimulation were stable.A higher plateau together with a faster response recovery
indicates that the time constant of leaving the desensitized state,
and therefore Epi unbinding from the desensitized double-
mutated receptors, is substantially faster than in the WT.
3.3. Inhibition
The competitive antagonist (+)tubocurarine (TC) was used
to test whether mutated amino acids are also involved in the
interaction with molecules which do not induce the open channel
conformation. TC was applied at varying concentrations as a 3 s
prepulse followed by coapplication with Epi at the concentra-
tion of its EC50 for the given receptor variant. Epi was chosen as
the prototype agonist because responses to other agonists in
mutated receptors were small and often undetectable. Concen-
tration–inhibition dependence was used to calculate Ki for the
WT and mutated receptors using the modified Cheng–Prusoff
formula [17–19]. Only double-mutated receptors had a Ki value
that was significantly higher than that of the WT (Table 4)
(Fig. 6). It indicates that receptor interaction with TC is affec-
ted by each single mutation to a much lower degree than the
interaction with agonists.
The classical agonists Nic, ACh and CCh are almost unable
to activate the double-mutated receptor. We tested their ability
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protocol as in experiments with TC (data shown in Table 4.). All
compounds lowered responses to 10 μM Epi (Fig. 6), Nic being
the most effective inhibitor with Ki almost 300 μM. The order
of Ki of Nic, ACh and CCh is identical with the order of their
EC50 in the WT.
4. Discussion
Our characterization of mutated α3β4 receptors showed
that both negatively charged amino acids D191 and D192 in the
F-loop of the β4 subunit participate in channel activation and
the desensitization mechanism. When tested separately, the
D191N mutation was generally more effective.
4.1. Activation
The parameters of activation of α3β4 WT receptor are in
good agreement with similar studies [20,21]. The finding that
maximal responses to ACh, Cyt, Nic and CCh hardly reached
65% of maximal response to Epi can be further analysed using
a simplified model of receptor activation, described in detail
elsewhere [22,23]. During this analysis the maximal relative
response to an agonist is given as 100%·L/(L+1) where L is the
equilibrium constant of channel gating [24]. It can be shown
that if the maximal response to the agonist does not exceed 65%
of maximal response to Epi, then L for this agonist is below
approximately 1.9, regardless of L for Epi. The Hill coefficient
being between 1.5 and 2 indicates that the occupation of both
binding sites by an agonist is necessary to induce effective
channel opening. Moreover, the Hill coefficient values together
with low L values imply high degree (10–100) of positive
cooperativity between binding sites for ACh, Nic, Cyt and CCh
in this model.
Generally, the increase in EC50 for Epi and Nic is similar,
which is in contrast with the 3.5–5-fold diminished responses
to Nic relative to those to Epi. In the WT, the maximal Nic
response is around 65% of the maximal Epi responses (Fig. 2),
whereas in the D191N and D192N receptors responses to
Nic are only 14% and 17% of the Epi responses, respectively
(Fig. 3). This striking difference could indicate that the chan-
ges in EC50 for Epi and Nic are caused by different mecha-
nisms. With Nic it might be a substantial decrease in L,
indicating a decreased efficacy of channel opening and increase
in EC50. Only this kind of change could explain the decrease
in Nic maximal response relative to Epi. That a decreased
cooperativity between both binding sites or direct change in
microscopic equilibrium constant for Nic binding to the first
binding site of the closed receptormight contribute to this increase
in EC50 is unlikely, since they are not connected to any change in
maximal response amplitude. Also, analysis of the competitive
inhibition of Epi responses in the double-mutated receptor by
Nic indicates that binding is not substantially diminished, as will
be discussed later. In terms of the allosteric model of channel
activation— the affinity of the open state to Nic is decreased by
mutations more than the affinity of open state to Epi. The affinity
of the closed state to Nic was perhaps even enhanced.The mechanism underlying the increased EC50 of mutated
receptors to Epi could be explained by a comparison with the
role of ɛ D175 in human muscle receptor, which corresponds
to position 189 in the F-loop of the β4 subunit. Sine et al. [25]
found that the D175N mutation decreases channel open pro-
bability and reduces closed state affinity 17-fold in one case of
congenital myasthenic syndrome.
The complete loss of the ability of ACh, Cyt and CCh to
activate the double-mutated receptor is in contrast with anta-
gonistic behavior of ACh and CCh (Fig. 6). We could conclude
that it is the efficacy of those agonists rather than ligand bind-
ing that is substantially affected.
4.2. Desensitization
Most reports concerning amino acids identified as important
for the desensitization process focus on the M2 transmembrane
domain and especially on α7 canonical L247 [6,26]. Mutations
in α7 L247 make the channel's desensitized state permeable to
ions. The α7 E172 residue is connected to channel potentiation
by Ca2+ ions [14,27]. However, its neutralization also partially
compensates the changes induced by the L247Kmutation in α7,
indicating a role in the interaction of the desensitized receptor
with the agonist [28].
The influence of calcium cations on α3β4 receptor activation
and desensitization is less understood than in α7 receptors.
Measurements of channel activation at various Ca2+ concentra-
tions revealed a significant decrease in responses at increased
Ca2+ on α3β4 [21]. It could not be excluded by analogy with the
α7 receptor that the role of negatively charged amino acids in
the F-loop is also mediated by the binding of the Ca2+ ion.
The change in the degree of desensitization could also be
compared with the role of ɛ D175 in one of the congenital
myasthenic syndromes [25], which is also important in channel
activation as mentioned above. The neutralization of this ne-
gative charge leads to a progressive decrease in the affinity of
the desensitized state to the agonist (800-fold).
These two groups of data could indicate the possible im-
portance of the F-loop in connecting binding site occupation
by an agonist with conformational changes leading to channel
opening and desensitization.
Moreover, the return from the desensitized state is substan-
tially accelerated in the double-mutated receptor. The long-term
desensitization of a wild-type α3β4 receptor by a higher con-
centration of Epi indicates that the corresponding rate constant
is extremely low and the binding constant of the desensitized
state for Epi is much higher than that of the resting state. The
decreased extent of desensitization and acceleration of resensi-
tization could indicate a decreased affinity of the desensitized
state to Epi.
4.3. Antagonist action
In electrophysiological experiments, the antagonist activity
could only be assessed as the comparative inhibition of ago-
nist activity. The concentration of the antagonist necessary to
decrease the control response to 50% depends not only on
870 J. Lindovský et al. / Biochimica et Biophysica Acta 1778 (2008) 864–871mutation-induced changes in antagonist binding itself, but also
on possible changes in the EC50 of the agonist. On the other hand
the measure of the ability of the antagonist to bind to its binding
site, the inhibition constant Ki, is independent of agonist bind-
ing and could be calculated from the IC50 values determined for
any agonist concentration.
The IC50 of TC for α3β4 may depend strongly on the
receptor source. In the bovine receptor Ki was 0.1 μM [29],
while in the rat receptor Ki was 20 μM [30]. Both results were
obtained by measuring TC competition with 3H Epi binding.
The finding that the interaction of the antagonist TC with
the binding site is also influenced by point mutations, but to a
lower extent, could be explained in at least two ways. Binding
site epitopes that were changed by the mutations interact with
the agonist molecule more strongly than with the antagonist
molecule. Antagonist binding is stabilized by interaction with
the unchanged epitopes. Another explanation is that both li-
gands interact with identical epitopes, but the EC50 of the
agonist is enhanced by allosteric conformation changes con-
nected with the cooperativity between two binding sites,
channel opening and desensitization. As the binding of the
antagonist is not stabilized in this way, changes putatively
weakening such allosteric phenomena cannot contribute to
changes in antagonist binding. Analysis of the interaction of
the mutated receptor with TC could be complicated by the fact
that in neuronal receptors containing the β4 subunit, TC is
able to act as not only a competitive inhibitor [31]. It was
found that receptors with one binding site occupied by ACh
and the second binding site occupied by TC could still open
and contribute to the ionic current.
4.4. Nic, ACh and CCh as partial agonists
The ability of Nic, ACh and CCh to serve as competitive
antagonists indicates that these ligands bind to the double-
mutated receptor. The interpretation of the comparison of the
EC50 of agonists (ACh, Nic or CCh) in the WTwith their Ki for
the double-mutated receptor depends strongly on the model of
allostery between the binding sites. The ratio Ki/EC50 for Nic
is 3.6, for ACh is 9.4 and for CCh is 2.6. To analyze this
relationship we again used an approach based on a simplified
model of the relationship between the macroscopic constants
EC50 and nH with microscopic parameters such as the degree
of allostery between both binding sites and equilibrium cons-
tant for channel gating described in detail elsewhere [22,23].
Since the Hill coefficient for activation of the WT by these
agonists is 1.8–2 and assuming that the equilibrium constant
for channel gating L is less than 2, we could estimate the
necessary degree of allostery between the binding sites to be 10–
100-fold. Therefore the equilibrium constant for binding to the
first binding site should be 5–20 times higher than the measu-
red EC50. This means that the equilibrium binding constant of
the closed wild-type receptor could be even higher than the
inhibition constant Ki of the double-mutated receptor. This
suggests that in the double-mutated receptor, Nic and CCh
binding to the closed receptor is at least undiminished if not
enhanced. The inhibition constant for ACh permits theexplanation that there is a slight weakening of its binding to
the double-mutated receptor. Taken together, this indicates that
the loss of ability of these agonists to activate the double-
mutated receptor is entirely caused by changes in the last step
of the activation — in the probability of channel opening.
However, the possibility remains that former agonists binding
to the double-mutated receptor cannot cause channel opening
but still remain cooperative.
The alternative explanation is that the possible increase in
affinity of the double-mutated receptor to former agonists/bloc-
kers is a product of the allosteric mechanism [32], where the
loss of activating properties is caused by a decrease in the affinity
of the opened state accompanied by an increase in the affinity of
the closed state. A similar pattern could also be observed in the
decrease of the affinity of the desensitized state to Epi.
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